share_log

CardioComm Solutions Provides Update Respecting Debt Settlement

CardioComm Solutions Provides Update Respecting Debt Settlement

CardioComm解决方案就债务结算提供更新
newsfile ·  07/08 18:37

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to provide an update respecting its proposed debt settlement transactions with certain creditors (the "Creditors") of the Company (see CardioComm's news release dated June 3, 2024 for CardioComm's initial announcement). Pursuant to debt settlement agreements with the Creditors, the Company will now issue an aggregate of 41,909,368 common shares of the Company ("Shares") to the Creditors at a deemed price of $0.01 per Share to settle an aggregate of $419,093.68 in outstanding debt owed by the Company to the Creditors. The debt to be settled includes $318,786.12 owed to non-arm's length parties which will be settled by the issuance of 31,878,612 Shares, which non-arm's length party debt includes $44,360.41 in Company expenses paid for by such non-arm's length parties. When issued, the Shares will be subject to a four month hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The debt settlement transactions and the issuance of the Shares thereunder is subject to receipt of approval from the TSX Venture Exchange.

安大略省多伦多-(Newsfile股份有限公司-2024年7月8日)- CardioComm Solutions,Inc.(TSXV:EKG)("CardioComm"或"公司"),是全球医疗消费类心脏监测和医疗心电图("ECG")软件解决方案的供应商,荣幸地提供有关与公司的某些债权人("债权人")拟议的债务结算交易的最新消息(请参见CardioComm于2024年6月3日发布的有关CardioComm首要公告的新闻稿)。根据与债权人的债务结算协议,公司现在将以每股0.01美元的看盘价格发行公司的共计41,909,368股普通股("股票")给债权人,以偿还公司欠债的总额419,093.68美元。待发行后,股票将根据适用的证券法规和TSX Venture Exchange的政策受到为期四个月的限售期的限制。债务结算交易及其下发的股票的发行受TSX Venture Exchange的批准。

Certain directors of the Company participated in the debt settlement transactions, and each transaction with a director is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). Each transaction with a director of the Company is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of each transaction does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101.

公司的某些董事参与了债务结算交易,并且与董事的每笔交易均被视为根据多边协议61-101("MI 61-101")下定义的"关联方交易"。每个与公司董事交易的交易均免除MI 61-101的正式估值和少数股东批准要求,因为每个交易的公允市场价值均不超过公司的市场总值的25%,按MI 61-101的规定确定。

To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at and .

要了解有关CardioComm产品的更多信息以及有关HeartCheck ECG设备集成的更多更新,请访问公司网站。

About CardioComm Solutions

关于CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

CardioComm Solutions的专利和专有技术用于诊断和管理心脏病患者的记录,查看,分析和存储心电图产品。通过外部分销网络和北美销售团队的组合,该产品在全球销售。 CardioComm Solutions已获得ISO 13485认证,符合HIPAA,并获得欧盟(CE标志),美国(FDA)和加拿大(Health Canada)的清关。

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com

欲了解更多信息请联系:
Etienne Grima,首席执行官
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

前瞻性声明 本新闻稿中包括的关于未来表现和结果、预期、规划、策略、重点、承诺和其他声明(包括与我们社会、环境和其他可持续性目标有关的声明)的非历史事实的前瞻性声明,是根据美国联邦证券法的定义而作出的前瞻性声明。本新闻稿中关于我们环境和其他可持续性计划和目标的前瞻性声明以及其他声明并不意味着这些声明对于投资者、我们的业务、运营结果、财务状况、前景或策略、对我们在可持续发展事项上的影响或其他当事方来说均是重要的,或者必须披露在我们向证券交易委员会(“SEC”)或其他监管机构的备案中。此外,历史、现有及未来涉及社会、环境和可持续性的相关声明可能是基于仍在发展的衡量进展的标准、不断演变的内部控制和流程以及假设,在将来可能会发生变化。前瞻性声明基于当前的信仰、期望和假设,并受到可能导致实际结果与前瞻性声明有实质性差异的重大风险、不确定性和情况变化的影响。
本发布可能包含某些前瞻性声明和与CardioComm Solutions的财务状况、经营业绩和业务有关的某些前瞻性信息以及CardioComm Solutions关于这些项目的某些计划和目标。这些声明和信息反映了管理层的目前信仰,并基于目前可供管理层使用的信息。nature,forward-looking statements and forward-looking information involve risk and uncertainty因为forward-looking statements和forward-looking information涉及到将来会发生的事件和情况,并且有很多因素可能会使实际结果和发展与这些forward-looking statements和forward-looking information所表达或暗示的结果和发展有所不同。

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

在评估这些陈述时,读者不应过分依赖前瞻性陈述和前瞻性信息。公司不会对本发布中包含的前瞻性陈述和前瞻性信息承担任何更新的义务,除了适用法律(包括但不限于51-102国家工具(持续披露义务)第5.8(2)节)要求的情况之外。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX Venture Exchange及其监管服务提供者(如TSX Venture Exchange的政策中所定义的那样)均不对本发布的充分性或准确性承担责任。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发